| 000 | 01884 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250516172337.0 | ||
| 264 | 0 | _c20140512 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1879-2472 | ||
| 024 | 7 |
_a10.1016/j.thromres.2013.09.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTomita, Hideharu | |
| 245 | 0 | 0 |
_aPatient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients. _h[electronic resource] |
| 260 |
_bThrombosis research _cNov 2013 |
||
| 300 |
_a537-42 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 |
_aAsian People _xgenetics |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xdrug therapy |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aJapan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aKadokami, Toshiaki | |
| 700 | 1 | _aMomii, Hidetoshi | |
| 700 | 1 | _aKawamura, Natsumi | |
| 700 | 1 | _aYoshida, Masayoshi | |
| 700 | 1 | _aInou, Tetsuji | |
| 700 | 1 | _aFukuizumi, Yutaka | |
| 700 | 1 | _aUsui, Makoto | |
| 700 | 1 | _aFunakoshi, Kouta | |
| 700 | 1 | _aYamada, Satoshi | |
| 700 | 1 | _aAomori, Tohru | |
| 700 | 1 | _aYamamoto, Koujiro | |
| 700 | 1 | _aUno, Tsukasa | |
| 700 | 1 | _aAndo, Shin-Ichi | |
| 773 | 0 |
_tThrombosis research _gvol. 132 _gno. 5 _gp. 537-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.thromres.2013.09.003 _zAvailable from publisher's website |
| 999 |
_c23121742 _d23121742 |
||